The Carillon Mitral Contour System is the only commercially available indirect mitral annuloplasty device, designed to treat a broad and expanding population of patients living with functional mitral ...
Cardiac Dimensions announced today that it published three manuscripts providing new evidence supporting its Carillon mitral ...
NATIONAL HARBOR, MD—Patients with functional mitral regurgitation (MR) treated with the Carillon device have sustained benefit and a 56.2% survival rate out to 5 years, according to results of a ...
KIRKLAND, Wash.--(BUSINESS WIRE)--Cardiac Dimensions ®, a leader in the development of innovative, minimally invasive treatment modalities to address patients suffering from heart failure with ...
Funds Expected to Support Enrollment in U.S. Pivotal EMPOWER Trial and European Commercial Expansion for Carillon Mitral Contour System® KIRKLAND, Wash.--(BUSINESS WIRE)--Cardiac Dimensions®, a leader ...
KIRKLAND, Wash — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today ...
Please provide your email address to receive an email when new articles are posted on . Patients with congestive HF and grade 2 to 4 functional mitral regurgitation despite medical therapy who ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Patients with HF and functional mitral regurgitation who received a device for transcatheter ...
The Carillon system is a percutaneously delivered, coronary-sinus-based mitral annuloplasty device. A safety and feasibility trial now demonstrates low rates of major adverse events, with improvements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results